NHS England boosts HCV fund to L190M

NHS England increased its budget for new virological cures for HCV patients to L190 million ($290.2 million) from L40 million ($61.1 million) in 2014. The agency also issued an interim Sovaldi sofosbuvir and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson (NYSE:JNJ) and Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir from AbbVie Inc. (NYSE:ABBV). ...